Free Trial
OTCMKTS:NVZMY

Novozymes A/S Q4 2025 Earnings Results & Report

Novozymes A/S logo
$68.13 -0.46 (-0.67%)
As of 02:44 PM Eastern

Novozymes A/S missed analyst expectations on both earnings and revenue in its Q4 2025 results, released February 25, 2026. The company reported EPS of $0.35 versus the $0.7910 consensus estimate, while revenue of $1.18 billion fell short of the $1.22 billion estimate by $41.55 million.

Earnings Announcement Details

Quarter
Q4 2025
Time
Before Market Opens

Novozymes A/S EPS Results

Actual EPS
$0.35
Consensus EPS
$0.7910
Beat/Miss
Missed by -$0.4410
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Novozymes A/S Revenue Results

Actual Revenue
$1.18 billion
Expected Revenue
$1.22 billion
Beat/Miss
Missed by -$41.55 million
YoY Revenue Growth
N/A

Upcoming Earnings

Novozymes A/S' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Conference Call Resources

Novozymes A/S Q4 2025 Earnings FAQ

Novozymes A/S (OTCMKTS:NVZMY) reported earnings of $0.35 per share for Q4 2025, missing the consensus estimate of $0.7910. The report was announced on Wednesday, February 25, 2026.

Novozymes A/S reported revenue of $1.18 billion for Q4 2025, against a consensus estimate of $1.22 billion.

Novozymes A/S' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Novozymes A/S on the company's earnings history page.

Novozymes A/S Earnings Headlines

Novozymes A/S (NVZMY) Q2 2026 Earnings Call Transcript
Did you grab your copy yet?
Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.tc pixel
Novonesis (Novozymes) B ADR NVZMY
Novozymes AS DRC (NVZMY)
See More Novozymes A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novozymes A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novozymes A/S and other key companies, straight to your email.

About Novozymes A/S

Novozymes A/S (OTCMKTS:NVZMY) was a Danish biotechnology company specializing in biological solutions based on enzymes, microorganisms and related technologies. Its products were designed to help businesses improve manufacturing efficiency, reduce resource use and develop more sustainable alternatives to conventional chemical processes.

The company supplied enzyme and microbial products for a range of industries, including household care, food and beverages, agriculture, animal health, bioenergy and industrial manufacturing. Applications included laundry and cleaning products, baking and brewing, starch processing, animal feed, crop-related solutions and the production of biofuels and other biobased materials.

Novozymes was established as an independent company in 2000 after being separated from Novo Nordisk and served customers across global markets through research, production and commercial operations in multiple regions. In January 2024, Novozymes combined with Chr. Hansen, another Danish bioscience company, to form Novonesis. Ester Baiget served as Novozymes’ president and chief executive officer before and during the combination process.

View Novozymes A/S Profile